According to MRFR, the Americas Cancer Immunotherapy Market is on a high-growth trajectory, expected to reach USD 118.27 billion by 2032 from USD 100.54 billion in 2024, growing at a 15.32% CAGR. Within this market, monoclonal antibodies (mAbs) remain a critical product category, offering high specificity in targeting cancer antigens. These biologic drugs have revolutionized oncology care by enhancing immune responses against tumors while minimizing collateral damage to healthy cells. In the Americas, mAbs are widely used for cancers such as breast, lung, and colorectal, with significant clinical success in prolonging survival rates. The pipeline for monoclonal antibodies is robust, supported by collaborations between biotech firms, pharmaceutical giants, and research institutions. Hospitals dominate the distribution channel for mAbs, but outpatient specialty clinics are increasing their share as treatment protocols evolve toward more convenient administration settings. The expanding clinical evidence base, combined with ongoing regulatory approvals, positions mAbs as a cornerstone of the immunotherapy market in the Americas.